CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administrationWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug616 Community Referral as appropriate Wiki 1.00
drug595 Cognitive Behavioral Therapy Wiki 0.71

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D009771 Obsessive-Compulsive Disorder NIH 1.00
D003193 Compulsive Personality Disorder NIH 1.00
D003192 Compulsive Behavior NIH 1.00

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0000722 Obsessive-compulsive behavior HPO 0.71

There is one clinical trial.

Clinical Trials

1 Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19

Covid-19 infection is due to SARS-CoV-2 member of the Coronavirus family represented by SARS- and MERS-CoVwith neuronal tropism capacity for the brainstem and thalami. Dexmedetomidine has(i) central antihypertensive (ii) sedative and (iii) neuroprotective properties and is often used during patient recovering after mechanical ventilation withdrawal. Dexmedetomidine administration could change the immunomodulatory profile of Covid-19 patients and reduce inflammatory response.CAM-ICU scores and Blood samples from Covid-19 ICU patients will be collected at 4 different timepoints (before Dexmedetomidine administration, at D2, D7 and M6) to analyse the inflammatory profile with different approaches:i) chromatin accessibility, ii) transcriptome analysis, iii) inflammatory cytokines and chemokines levels.

NCT04413864 SARS-CoV 2 Other: Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration

Primary Outcomes

Measure: Change of inflammatory cytokines concentration (mmol / L) in Covid19 + patients from Baseline at 6 months

Time: Month6

Secondary Outcomes

Measure: Change of interrelationship between inflammation (cytokines levels) and ICU delirium in Covid19 + patient from Baseline at 6 months

Time: Month6

Measure: Modification in inflammatory genes expressed (expressed / non expressed) in PBMC between Baseline and M6

Time: Month6

Measure: Change in quantity of chromatine's openings (chromatin accessibility profiles) in ICU patient recovering from covid19 infection

Time: Day2, Month6

Measure: Change in genes expression in Covid-19 patient with delirium in ICU between Day2 and Month6

Time: Day2, Month6

No related HPO nodes (Using clinical trials)